Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Repligen Community
NasdaqGS:RGEN Community
1
Narratives
written by author
0
Comments
on narratives written by author
12
Fair Values set
on narratives written by author
Create a narrative
Community Investing Ideas
Repligen
Popular
Undervalued
Overvalued
Repligen
AN
AnalystConsensusTarget
Consensus Narrative from 18 Analysts
Biomanufacturing Expansion Will Create New Global Opportunities
Key Takeaways Strong demand in biomanufacturing and effective market expansion are driving sustained revenue growth and improved margins for Repligen. Strategic investments in innovation, operational efficiency, and global diversification position the company for continued resilience and long-term earnings stability.
View narrative
US$179.75
FV
33.8% undervalued
intrinsic discount
14.85%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
11 days ago
author updated this narrative
Your Valuation for
RGEN
RGEN
Repligen
Your Fair Value
US$
Current Price
US$118.91
52.5% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-14m
1b
2015
2018
2021
2024
2025
2027
2030
Revenue US$1.3b
Earnings US$164.9m
Advanced
Set Fair Value